0001493152-21-007814.txt : 20210401 0001493152-21-007814.hdr.sgml : 20210401 20210401212946 ACCESSION NUMBER: 0001493152-21-007814 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210330 FILED AS OF DATE: 20210401 DATE AS OF CHANGE: 20210401 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Yeh Yung-Ping CENTRAL INDEX KEY: 0001850320 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-35817 FILM NUMBER: 21800388 MAIL ADDRESS: STREET 1: C/O VYANT BIO, INC. STREET 2: 201 ROUTE 17 NORTH, 2ND FLOOR CITY: RUTHERFORD STATE: NJ ZIP: 07070 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Vyant Bio, Inc. CENTRAL INDEX KEY: 0001349929 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MEDICAL LABORATORIES [8071] IRS NUMBER: 043462475 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 2370 STATE ROUTE 70 WEST STREET 2: SUITE 310 CITY: CHERRY HILL, STATE: NJ ZIP: 08002 BUSINESS PHONE: 201.528.9200 MAIL ADDRESS: STREET 1: 2370 STATE ROUTE 70 WEST STREET 2: SUITE 310 CITY: CHERRY HILL, STATE: NJ ZIP: 08002 FORMER COMPANY: FORMER CONFORMED NAME: CANCER GENETICS, INC DATE OF NAME CHANGE: 20111216 FORMER COMPANY: FORMER CONFORMED NAME: CANCER GENETICS INC DATE OF NAME CHANGE: 20060117 4 1 ownership.xml X0306 4 2021-03-30 0 0001349929 Vyant Bio, Inc. VYNT 0001850320 Yeh Yung-Ping C/O VYANT BIO, INC. 2 EXECUTIVE CAMPUS 2370 STATE ROUTE 70, SUITE 310 CHERRY HILL, NJ 08002 1 1 0 0 Chief Innovation Officer Common Stock, $0.0001 par value 2021-03-30 4 J 0 1328602 A 1328602 D Stock option (right to buy) 1.56 2021-03-30 4 J 0 51825 0 A 2030-05-22 Common stock 51825 51825 D Stock option (right to buy) 4.61 2021-03-30 4 A 0 150000 0 A 2031-03-30 Common stock 150000 150000 D Pursuant to that certain Agreement and Plan of Merger, dated as of August 21, 2020, as amended, by and among Cancer Genetics, Inc. now known as Vyant Bio, Inc. ("Issuer"), CGI Acquisition, Inc., a Minnesota corporation and a wholly-owned subsidiary of Issuer ("Merger Sub") and StemoniX, Inc., a Minnesota corporation ("StemoniX") (the "Merger Agreement"), Reporting Person received shares of the Issuer's common stock, $0.0001 par value (the "Common Stock") in exchange shares of StemoniX common stock, $0.0001 owned prior to the merger. Pursuant to that certain Agreement and Plan of Merger, dated as of August 21, 2020, as amended, by and among Cancer Genetics, Inc. now known as Vyant Bio, Inc. ("Issuer"), CGI Acquisition, Inc., a Minnesota corporation and a wholly-owned subsidiary of Issuer ("Merger Sub") and StemoniX, Inc., a Minnesota corporation ("StemoniX") (the "Merger Agreement"), Reporting Person received options to purchase shares of Common Stock of the Issuer in exchange for options to purchase shares of StemoniX common stock, $0.0001 owned prior to the merger. Subject to continued employment, 51,825 options vest upon the achievement of certain milestones. The option award was made in accordance with the terms of the Issuer's 2021 Equity Incentive Plan. Subject to continued employment, the option vests as to 25% of the shares on March 30, 2022 with the remaining shares to vest in equal monthly installments over a period of 36 months commencing on April 30, 2022. /s/ John A. Roberts, attorney-in-fact 2021-04-01